Group 1: Company Performance and Challenges - The company faced a decline in gross margin and net profit due to factors such as national drug procurement policies, adjustments in medical insurance settlement methods, and rising raw material prices in 2024 [3] - In Q4 2024, the company reported a net loss of CNY 75.208 million, primarily due to decreased revenue and gross margin in the pharmaceutical distribution and medical services sectors, along with increased non-recurring losses [6] - The management acknowledged the concerns of investors regarding the company's performance and emphasized the importance of protecting investor rights [3] Group 2: Strategic Responses and Future Plans - The management is actively addressing challenges by enhancing medical service quality, optimizing long-term customer accounts in the pharmaceutical distribution sector, and promoting the development of traditional Chinese medicine [3] - The company plans to continue its efforts in market management and operational compliance to ensure long-term development and value creation for investors [3] - The company has implemented a share buyback and cash dividend strategy, distributing a total of CNY 171.2894 million in cash dividends in 2024, which accounted for 168.96% of the net profit attributable to shareholders [6] Group 3: Subsidiary Operations and Legal Matters - The subsidiary, Keke Pharmaceutical, is currently operating normally despite being under investigation, and the company will disclose any significant developments as required [4] - The management reassured investors that the ongoing legal matters would not adversely affect the subsidiary's operations or the company's overall performance [6]

证券代码：002390 证券简称：信邦制药 公告编号：2025-017 贵州信邦制药股份有限公司 关于为下属医院提供担保的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 贵州信邦制药股份有限公司（以下简称"公司"）于 2025 年 4 月 11 日召开的第九届董事会第六次会议审议通过了《关于 2025 年度 向银行申请授信及担保事项的议案》，董事会同意 2025 年度公司及 合并报表范围内子公司（以下简称"子公司"）向银行申请总额不超 过 210,000 万元的银行综合授信，公司为子公司提供担保额度不超过 170,000 万元，其中为资产负债率低于 70%的子公司提供担保的额度 不超过 120,000 万元，为资产负债率 70%以上的子公司提供担保的额 度不超过 50,000 万元。详情可参见 2025 年 4 月 15 日刊登于中国证 券报、证券时报及巨潮资讯网（http://www.cninfo.com.cn）的《关 于公司 2025 年度向银行申请授信及担保事项的公告》（公告编号： 2025-011）。上述事项已于 2025 年 5 月 7 日经公 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 特别提示 1、本次股东大会无增加、否决或修改提案的情况。 2、本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议召开情况 证券代码：002390 证券简称：信邦制药 公告编号：2025-016 贵州信邦制药股份有限公司 2024年度股东大会决议的公告 1、会议通知情况 贵州信邦制药股份有限公司（以下简称"公司"）于 2025 年 4 月 15 日 在 《 中 国 证 券 报 》 、 《 证 券 时 报 》 和 巨 潮 资 讯 网 （http://www.cninfo.com.cn）刊登了《关于召开 2024 年度股东大 会的公告》（公告编号：2025-013）。 2、会议召集人：公司第九届董事会 3、会议主持人：董事长安吉女士 4、会议时间：2025 年 5 月 7 日 下午 14：00 5、会议地点：贵州省贵阳市乌当区新添大道北段 83 号科开 1 号苑 15 楼会议室 6、股权登记日：2025 年 4 月 28 日 7、召开方式：现场书面投票与网络投票相结合的方式 8、本次股东大会的召集、召开符合《公 ...

国浩律师（上海）事务所 法律意见书 国浩律师（上海）事务所 关于贵州信邦制药股份有限公司 2024 年度股东大会的法律意见书 致：贵州信邦制药股份有限公司 贵州信邦制药股份有限公司（以下简称"公司"）2024 年度股东大会（以下简 称"本次股东大会"）现场会议定于 2025 年 5 月 7 日下午 14：00 在贵州省贵阳市 乌当区新添大道北段 83 号科开 1 号苑 15 楼会议室召开，国浩律师（上海）事务 所（以下简称"本所"）接受公司的委托，指派本所律师出席会议，并依据《中华 人民共和国证券法》、《中华人民共和国公司法》和《贵州信邦制药股份有限公 司章程》（以下简称《公司章程》）出具本法律意见书。 本所律师已经按照有关法律、法规的规定对本次股东大会召集、召开程序是 否合法及是否符合《公司章程》、股东大会召集人资格的合法有效性、出席会议 人员资格的合法有效性和股东大会表决程序、表决结果等发表法律意见。法律意 见书中不存在虚假、严重误导性陈述及重大遗漏，否则愿意承担相应的法律责任。 本所律师是根据对事实的了解和对法律的理解发表法律意见。 本法律意见书依据国家有关法律、法规的规定而出具。 本所律师同意将本法律 ...

Financial Performance - The company's revenue for Q1 2025 was ¥1,441,207,780.35, a decrease of 8.93% compared to ¥1,582,449,461.55 in the same period last year[2] - Net profit attributable to shareholders was ¥41,244,211.17, down 29.89% from ¥58,824,843.56 year-on-year[2] - Basic earnings per share decreased by 33.33% to ¥0.02 from ¥0.03 in the same period last year[2] - Operating profit for the period was CNY 61,765,904.02, compared to CNY 80,596,910.56 in the previous period[16] - The total comprehensive income for the period was CNY 53,861,041.80, down 25% from CNY 71,693,790.38 in the previous period[17] Cash Flow - The net cash flow from operating activities increased significantly by 2,059.91%, reaching ¥55,020,064.59 compared to ¥2,547,325.59 in the previous year[5] - Cash inflow from operating activities totaled CNY 1,445,098,460.85, down 6.3% from CNY 1,541,586,484.20 in the previous period[18] - Cash outflow from operating activities was CNY 1,390,078,396.26, a decrease of 9.7% compared to CNY 1,539,039,158.61 in the previous period[18] - The net cash flow from investing activities was -CNY 34,847,321.93, an improvement from -CNY 61,053,033.28 in the previous period[19] - The net cash flow from financing activities was -CNY 40,714,131.75, an improvement from -CNY 128,283,450.80 in the previous period[19] - The ending cash and cash equivalents balance was CNY 912,180,048.98, compared to CNY 543,901,118.54 in the previous period, indicating an increase[19] Assets and Liabilities - Total assets at the end of the reporting period were ¥9,016,153,188.07, a slight decrease of 0.13% from ¥9,028,336,478.89 at the end of the previous year[2] - Total liabilities amounted to CNY 2,015,625,494.24, an increase from CNY 2,008,414,826.86 in the previous period[13] - Cash and cash equivalents at the end of the period were CNY 985,249,525.33, down from CNY 1,015,515,313.40 at the beginning of the period[10] - Accounts receivable increased to CNY 2,596,090,541.54 from CNY 2,534,340,405.01[10] - Inventory decreased to CNY 1,015,339,000.49 from CNY 1,060,430,088.41[11] - Non-current assets totaled CNY 3,740,887,305.68, down from CNY 3,776,245,256.87[12] Shareholder Information - The company’s total equity attributable to shareholders increased by 0.61% to ¥6,751,300,632.76 from ¥6,710,056,421.59 at the end of the previous year[2] - The number of ordinary shareholders at the end of the reporting period was 66,968[6] Investment Income and Impairment - The company reported a 100% increase in investment income to ¥101,384.14, attributed to dividends received from investment projects[5] - The company experienced a decrease in credit impairment losses, with a loss of ¥1,582,518.96 compared to a loss of ¥3,343,367.45 in the previous year[5] Return on Equity - The weighted average return on equity was 0.61%, down 0.25 percentage points from 0.86% in the previous year[2] Audit Status - The company’s first quarter report was not audited[20]

证券代码：002390 证券简称：信邦制药 公告编号：2025-015 贵州信邦制药股份有限公司 关于参加投资者集体接待日活动暨2024年度业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 贵州信邦制药股份有限公司（以下简称"公司"）已于 2025 年 4 月 15 日在巨潮资讯网（www.cninfo.com.cn）披露了《2024 年年 度报告》，为加强公司与投资者的交流互动，便于投资者进一步了 解公司 2024 年度经营情况及其他关切问题，公司将参加在贵州证监 局指导下，贵州证券业协会联合深圳市全景网络有限公司举办的 2025 年贵州辖区上市公司投资者集体接待日（2024 年度业绩说明会） 活动，具体安排如下： 一、业绩说明会的安排 次业绩说明会公司将提前向广大投资者开展问题征集，提问通道自 本公告发出之日起开放至 2025 年 5 月 8 日截止，请通过微信关注 "贵州资本市场"公众号，发送关键词"提问"即可进入专区提问。 公司将在本次说明会上对投资者普遍关注的问题进行回答。 欢迎广大投资者积极参与本次年度业绩说明会。 特此公告。 贵州 ...

Core Viewpoint - Xinfang Pharmaceutical (SZ002390) reported a decline in both revenue and net profit for the year 2024, indicating significant challenges in its business operations [1][3]. Financial Performance - In 2024, Xinfang Pharmaceutical's operating revenue was 6.03 billion yuan, a decrease of 6.63% compared to 2023 [2][3]. - The net profit attributable to shareholders was 101 million yuan, down 64.7% year-on-year, marking the lowest level in nearly six years [2][3]. - The net profit after deducting non-recurring gains and losses was 165 million yuan, a decline of 38.29% from the previous year [2][3]. - The net cash flow from operating activities was 635 million yuan, down 19.69% year-on-year [2][3]. - Basic and diluted earnings per share were both 0.05 yuan, a decrease of 66.67% compared to 0.15 yuan in 2023 [2][3]. Asset and Equity Position - Total assets at the end of 2024 were approximately 9.03 billion yuan, a decrease of 2.34% from the previous year [2][3]. - The net assets attributable to shareholders were about 6.71 billion yuan, down 2.08% year-on-year [2][3]. Segment Performance - The pharmaceutical distribution segment generated 4.75 billion yuan in revenue, a decline of 10.03%, with a gross margin of 9.17% [3][4]. - The medical services segment reported revenue of 1.64 billion yuan, down 8.48%, with a gross margin of 9.55% [3][4]. - The traditional Chinese medicine manufacturing segment achieved revenue of 939 million yuan, an increase of 11.28%, but with a gross margin of 47.89%, down 1.83% [3][4]. Non-Recurring Gains and Losses - In 2024, non-recurring losses amounted to approximately 63.94 million yuan, compared to a gain of 19.33 million yuan in the previous year [5][6]. - The largest component of non-recurring losses was from "other operating income and expenses," totaling 67 million yuan [5][6]. Investment and Other Income - Investment income for the year was approximately 1.30 million yuan, a significant increase of 264.84% compared to the previous year [7]. - Operating expenses decreased by 43.07% in the first three quarters of 2024, indicating a potential improvement in cost management [6][7].

Core Viewpoint - Xinfang Pharmaceutical (SZ002390) reported a decline in both revenue and net profit for the year 2024, indicating financial challenges for the company. Financial Performance - In 2024, Xinfang Pharmaceutical's operating revenue was 6.03 billion yuan, a decrease of 6.63% compared to 2023, which was 6.46 billion yuan [2] - The net profit attributable to shareholders was 101 million yuan, down 64.7% from 287 million yuan in 2023 [2] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 165 million yuan, a decrease of 38.29% from 268 million yuan in 2023 [2] - The net cash flow from operating activities was 635 million yuan, down 19.69% from 791 million yuan in 2023 [2] - Basic and diluted earnings per share were both 0.05 yuan, a decline of 66.67% from 0.15 yuan in 2023 [2] - The weighted average return on net assets was 1.50%, down 2.69 percentage points from 4.19% in 2023 [2] - Total assets at the end of 2024 were approximately 9.03 billion yuan, a decrease of 2.34% from 9.24 billion yuan at the end of 2023 [2] - Net assets attributable to shareholders were approximately 6.71 billion yuan, down 2.08% from 6.85 billion yuan at the end of 2023 [2] - The net profit for 2024 marked the lowest level in six years, with figures from 2019 to 2024 being 236 million yuan, 174 million yuan, 273 million yuan, 224 million yuan, 287 million yuan, and 101 million yuan respectively [2] Legal Issues - Xinfang Pharmaceutical's subsidiary, Guizhou Kekai Pharmaceutical Co., Ltd., is under investigation for alleged unit bribery, involving its actual controller An Huailue [3] - The company announced that it received a notification regarding the court's acceptance of the bribery case, but it does not expect significant adverse effects on its profits for the current and future periods [3]

Core Insights - The company reported a total revenue of 6.032 billion yuan in 2024, a year-on-year decline of 6.63%, with a net profit attributable to shareholders of 101 million yuan, down 64.70% year-on-year [1] - The core business segments include medical services, pharmaceutical distribution, and traditional Chinese medicine manufacturing, but the overall performance in 2024 was disappointing [1] Medical Services Segment - The medical services segment generated revenue of 1.636 billion yuan, a decrease of 8.48% year-on-year, with tumor hospital revenue at 792 million yuan and general hospital revenue at 845 million yuan [4] - Despite the revenue decline, the company made progress in medical quality, refined management, and brand building [4] - Initiatives included optimizing medical quality management, enhancing multi-disciplinary treatment models, and achieving significant academic contributions with 261 published articles, including 40 in SCI journals [4] Pharmaceutical Distribution Segment - The pharmaceutical distribution segment achieved revenue of 4.746 billion yuan, down 10.03% year-on-year, with drug revenue at 4.159 billion yuan and medical device revenue at 587 million yuan [6] - The company focused on customer structure adjustment and channel optimization to improve asset safety and fund efficiency [6] - Notable growth was seen in the DTP specialty pharmacy sales, which exceeded 100 million yuan, marking a 60% increase year-on-year [6] Pharmaceutical Manufacturing Segment - The pharmaceutical manufacturing segment reported revenue of 939 million yuan, an increase of 11.28% year-on-year, with traditional Chinese medicine pieces revenue at 622 million yuan, up 18.74% [7] - The company enhanced market management through commercial channel restructuring and training, achieving internal management efficiency [7] - The development and launch of new health products were completed, and the company implemented a traceability system for traditional Chinese medicine to ensure quality [7] Overall Performance and Future Outlook - Despite facing significant performance pressure in 2024, the company made strides in refined management and brand building across its three main segments [8] - Future efforts will be needed to improve operational efficiency and respond to market changes to tackle challenges posed by the industry environment [8]

Policy Developments - The National Medical Products Administration (NMPA) approved the registration of 308 medical device products as of March 2025, including 248 domestic Class III medical devices, 34 imported Class III medical devices, 19 imported Class II medical devices, and 7 medical devices from Hong Kong, Macau, and Taiwan [1] Drug Approvals - Chengdu Saijing Bio's ursodeoxycholic acid oral suspension has been approved as the first domestic generic Class 3.1 new drug for treating cystic fibrosis-associated liver disease (CFALD), filling a gap in the market for this indication [2] - Kowa Company's pemafibrate tablets have been approved in China for the treatment of dyslipidemia [3] - Merck Sharp & Dohme (MSD) announced that its nine-valent HPV vaccine has received approval for male use in China, targeting males aged 16-26, enhancing public awareness of HPV infections in men [5] Capital Market - Zhongjie Chaorun completed a Pre-A round financing of several million yuan, primarily for clinical trials of its artificial meniscus implant and commercialization of its innovative meniscus suturing device [4] Financial Reports - Aoyang Health reported a 2024 revenue of 2.01 billion yuan, a year-on-year decrease of 7.54%, with a net profit of 40.56 million yuan, down 18.36% [6] - Novogene announced a total revenue of 2.111 billion yuan for 2024, a year-on-year increase of 5.45%, with a net profit of 197 million yuan, up 10.52% [7] - Tianyi Medical reported a revenue of 419 million yuan for 2024, a year-on-year increase of 9.98%, but a net loss of 744,000 yuan [8] - Luoxin Pharmaceutical disclosed a net loss of 962 million yuan for 2024, despite a revenue increase of 11.99% to 2.647 billion yuan [9] - Dongxing Medical reported a revenue of approximately 435 million yuan for 2024, a slight increase of 0.4%, with a net profit of about 97.42 million yuan, up 0.21% [10] Public Sentiment - Xinbang Pharmaceutical announced the resignation of independent director Zhou Jun, with the company reporting a revenue of 6.032 billion yuan for 2024, down 6.63%, and a net profit of 101 million yuan, down 64.70% [11] - Shuangcheng Pharmaceutical warned of potential delisting risk due to expected negative net profit and revenue below 300 million yuan for 2024 [12]